Substitution of the Normal Levels of Iron and Hemoglobin in Pregnant Women With Iron Supplement
Primary Purpose
Prevention of Anemia
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Iron
Sponsored by

About this trial
This is an interventional treatment trial for Prevention of Anemia
Eligibility Criteria
Inclusion Criteria:
- Age more or equal of 18 years
- Registration consent
- Have complete 12h week of pregnancy
- Hemoglobin levels <10,5 ptl
- Hematocrit < 32 %
Exclusion Criteria:
- Age <18 years
- Absent registration consent
- Step of pregnancy less than 12 weeks
- Coadministration formulations iron oral or parenterally
- Background of liver kirrosis
- Background of aimosidirosis
- Background acquired or chronic aimatochromatosis
- Aplastic , Hemolytic anemia and chronic diseases
- Chronic pancreatitis
- Subjective renal or/and liver disease
- Hypothyroidism or yperthyreoeidismos
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
pregnant women
pregnant women with anemia
Arm Description
iron dosage 1 per day for 3 months
iron dosage 1 per day for 6 months
Outcomes
Primary Outcome Measures
Measured and reported effectiveness of iron in the treatment of iron deficiency in pregnant 2nd and 3rd quarter with questionnaire
Measured and reported effectiveness of iron in the treatment of iron deficiency in pregnant
Secondary Outcome Measures
adverse reactions
adverse reactions
Full Information
NCT ID
NCT02957643
First Posted
October 12, 2016
Last Updated
July 27, 2020
Sponsor
Hippocration General Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02957643
Brief Title
Substitution of the Normal Levels of Iron and Hemoglobin in Pregnant Women With Iron Supplement
Official Title
Treatment of Iron Defieciency Anemia
Study Type
Interventional
2. Study Status
Record Verification Date
July 2020
Overall Recruitment Status
Completed
Study Start Date
November 2016 (Actual)
Primary Completion Date
September 2017 (Actual)
Study Completion Date
September 1, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hippocration General Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of the study is to investigate the effectiveness of iron in the treatment of iron deficiency in pregnant 2nd and 3rd quarter. Every 30 days the investigators measure the hemoglobin, hematocrit and iron in serum and assess the course of treatment.
Detailed Description
The purpose of the study is to investigate the effectiveness of iron in the treatment of iron deficiency in pregnant 2nd and 3rd quarter. Every 30 days the investigators measure the hemoglobin, hematocrit and iron in serum and assess the course of treatment
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prevention of Anemia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
pregnant women
Arm Type
Placebo Comparator
Arm Description
iron dosage 1 per day for 3 months
Arm Title
pregnant women with anemia
Arm Type
Experimental
Arm Description
iron dosage 1 per day for 6 months
Intervention Type
Drug
Intervention Name(s)
Iron
Other Intervention Name(s)
oral iron
Intervention Description
oral treatment
Primary Outcome Measure Information:
Title
Measured and reported effectiveness of iron in the treatment of iron deficiency in pregnant 2nd and 3rd quarter with questionnaire
Description
Measured and reported effectiveness of iron in the treatment of iron deficiency in pregnant
Time Frame
up to 24 months
Secondary Outcome Measure Information:
Title
adverse reactions
Description
adverse reactions
Time Frame
up to 24 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age more or equal of 18 years
Registration consent
Have complete 12h week of pregnancy
Hemoglobin levels <10,5 ptl
Hematocrit < 32 %
Exclusion Criteria:
Age <18 years
Absent registration consent
Step of pregnancy less than 12 weeks
Coadministration formulations iron oral or parenterally
Background of liver kirrosis
Background of aimosidirosis
Background acquired or chronic aimatochromatosis
Aplastic , Hemolytic anemia and chronic diseases
Chronic pancreatitis
Subjective renal or/and liver disease
Hypothyroidism or yperthyreoeidismos
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
PANAGIOTIS MATSOUKATIDIS, MD,Msc
Organizational Affiliation
Aristotle University Of Thessaloniki, School of Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
CHARALABOS KOLVATZIS, MD
Organizational Affiliation
Aristotle University Of Thessaloniki, School of Medicine
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
email contact
IPD Sharing Time Frame
up to two years upon completion
IPD Sharing Access Criteria
email contact
Learn more about this trial
Substitution of the Normal Levels of Iron and Hemoglobin in Pregnant Women With Iron Supplement
We'll reach out to this number within 24 hrs